P50.06 First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate

Abstract

Treatment of first-line NSCLC harboring EGFR and HER2 exon 20 insertion mutation (ex20-ins) remains an unmet clinical need. Poziotinib (POZ), a new generation tyrosine kinase inhibitor (TKI), is under investigation in first and further-line setting as a potential targeted therapy. Data from the ZENITH20 ongoing trial (Cohort 3) demonstrated a median Progression-Free Survival (mPFS), an ORR and a DCR of 7.8 months (m), 28% and 86%, respectively, in patients (pts) with treatment naïve EGFR-ex20-ins NSCLC; however, chemotherapy (CT) with or without immunotherapy (IO) still remains the standard first-line in this subset.